Zhengye Biotechnology Holding (ZYBT) Other Accumulated Expenses (2024)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Other Accumulated Expenses of $20325.5 for Q4 2024.
Zhengye Biotechnology Holding (ZYBT) Other Accumulated Expenses (2024) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Other Accumulated Expenses for 1 consecutive years, with $20325.5 the latest figure, recorded in Q4 2024.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $20325.5 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $20325.5 (changed N/A YoY) and the FY2024 annual result came in at $20000.0, changed N/A from the prior year.
- Other Accumulated Expenses held at $20325.5 in Q4 2024 per ZYBT's latest filing.
- Over the last five years, Other Accumulated Expenses for ZYBT reached as high as $20325.5 in Q4 2024 and fell as low as $20325.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Zhengye Biotechnology Holding | 67.87 Mn | 60.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20,325.50 |